Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Roger's 1998 Short Picks -- Ignore unavailable to you. Want to Upgrade?

To: BDR who wrote (13918)	9/22/1998 1:29:00 AM
From: put2rich	Read Replies (1) \| Respond to of 18691

Dale, <<Incorporated 24 years ago, the company admits that in the ensuing 24 years it has not once reported a profit>> You meant ALTIF (a company) exists w/ 24 years in loss? Founders were billionaires or they just scammed it from many naive investors? I know most rookie investors lose money so may be they are the feed for things like ALTIF...But how come genuine brokerage like Prudential still give "accumulate" upgrade? Oh I will reshort small again in/out as usual. What did ALTIF do during that long time besides inventing the CJ and try to sell it? thanks

To: BDR who wrote (13918)	9/22/1998 1:46:00 AM
From: Roger A. Babb	Respond to of 18691

Dale, I agree on both HEPH and ALTIF, but we need those "dumb buyers" to create our shorting opportunities. For what it is worth, it looks to me that the market has made some sort of near term bottom and is headed up from here. Small caps turned up last week and Dow made a major reversal to the upside today. Very bullish. Shorts must be careful now.

To: BDR who wrote (13918)	9/22/1998 10:01:00 AM
From: Mama Bear	Respond to of 18691

"It ought to be an automatic, profitable short, but there are still buyers for this company's stock. Where do these people come from? They are the bane of the shorter's existence" While they may seem annoying in the immediate view, these are the same folks who run worthless stocks up and create short selling opportunities. Barb

To: BDR who wrote (13918)	9/22/1998 11:21:00 AM
From: craig crawford	Read Replies (1) \| Respond to of 18691

>> Another example to consider is ALTIF. Incorporated 24 years ago, the company admits that in the ensuing 24 years it has not once reported a profit. << Forget profits, they don't even have any revenues.

To: BDR who wrote (13918)	9/24/1998 11:03:00 PM
From: BDR	Read Replies (2) \| Respond to of 18691

Hollis-Eden Pharmaceuticals' Research Affiliate Commences Phase I/II Clinical Trials with Novel Anti-HIV Drug PR Newswire - September 23, 1998 13:43 SAN DIEGO, Sept. 23 /PRNewswire/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH) announced today that its research affiliate, Edenland, Inc. of Ireland, has commenced two Phase I/II clinical studies with approximately 40 HIV infected treatment naive patients (patients that have not taken any anti-HIV drugs) in South Africa. The studies are testing a novel compound as a monotherapy in dose escalation protocols utilizing two different formulations. The studies are intended to determine the safety and efficacy of this new anti-HIV therapy. The different formulations are intended to evaluate the best route of administration and bioavailability of this drug candidate. This investigational new drug has a novel mechanism of action to inhibit HIV replication. Quintiles Clindepharm, under the medical direction of Dr. Oppel Greeff, and the Medical University of Southern Africa are conducting the studies. The trials are expected to take three months. Additionally, Hollis-Eden is filing a company-sponsored Phase I/II clinical trial with this novel compound, HE2000, in collaboration with the National Institute of Virology in South Africa. This trial in treatment naive patients is intended to optimize the dosing regimen, safety and efficacy of HE2000. Together Hollis-Eden and Edenland Phase I/II protocols will study this new compound as a monotherapy in more than 80 treatment naive patients. In the United States, the company intends to file an investigational new drug (IND) application with the FDA to initiate Phase I/II clinicaltrials with HE2000 in the fourth quarter. "With the commencement of our clinical trials, I envision that the day is approaching when a cost-effective monotherapy will challenge the virus successfully. This new therapy not only offers hope to patients in developed countries but also may represent the first effective treatment option for the developing world," said Patrick T. Prendergast, Ph.D., founding scientist, Hollis-Eden Pharmaceuticals and chairman of Edenland Inc. >>>>>>>> They have a website now: holliseden.com but the links don't seem to work. Is HE2000 just their new name for INACTIVIN and REVERSIONEX. Inactivin is of course their name for DHEA. Short HEPH from 9/22 at 14 11/16.